Choosing and switching biologics for patients with severe asthma ? real-life data from the German Asthma Net (GAN) - Amsterdam 2025

Asthma biologics: transitions, timing and treatment optimisation

Chair(s): Maarten van den Berge, Simon Couillard

Session type: Poster session

Choosing and switching biologics for patients with severe asthma ? real-life data from the German Asthma Net (GAN)

Alexandra Lenoir

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Evaluation of biomarkers and a decision tree model for the treatment of asthma with omalizumab:a prospective cohort study

Yi Liu

Abstract

Towards personalised dosing intervals of biologics in severe asthma: a Dutch nationwide survey on interval extensions

C J M Marijnissen

Poster

Abstract

Proactive identification of Uncontrolled Severe Asthma Patients within Humber and North Yorkshire ICS to Address Inequalities in access to Asthma Biologics: The Pro-HNY-Bio Project

Shoaib Faruqi

Poster

Abstract

eNose Breath Analysis for Predicting Eosinophilic Asthma and Biologic Response in PRISM-UK

Nazanin Zounemat-kermani

Abstract

Predictive determinants of response to biological therapy in children and adults with severe asthma

Debora Maria Spitaleri

Poster

Abstract

Assesing treatment response to benralizumab with cuantitative scales. The FEOS rate. A multicenter study in Madrid, Spain.

David Romero Ribate

Poster

Abstract

Choosing and switching biologics for patients with severe asthma real-life data from the German Asthma Net (GAN)

Alexandra Lenoir

Poster

Abstract

Machine learning prediction of synergistic effects of anti-TSLP and Budesonide on airway epithelial integrity in asthma

Valentina Lazzara

Poster

Abstract

Real-world dosing interval extension of biologics in the Dutch severe asthma registry

C J M Marijnissen

Poster

Abstract

Tezepelumab in severe uncontrolled asthma, for naïve or switched patients?

Alberto González Hernández

Poster

Abstract

Modelling the impact of earlier biologic initiation in severe asthma patients

Simon Couillard

Poster

Abstract

Baseline biomarkers predicting remission of severe asthma after switching biologics

Susanne Hansen

Poster

Abstract

Stick or twist? FeNO predicts clinical benefit in patients switching from IL5/5R to IL4/13 blockade due to uncontrolled asthma

Elisa Landin Rey

Poster

Abstract

Variability in time to response in severe asthma biologics: a SHARP survey

Joseph Lanario

Poster

Abstract

Response to tezepelumab as a second-line biologic in a UK severe asthma population

Peer Ameen Shah

Poster

Abstract

Bio-RAMPA: Adverse Drug Reactions of Biological Therapies

Ana Rita Gaspar Ribeiro

Poster

Abstract

Switching biological treatment in severe asthma: A study on patient profiles and clinical outcomes

Hanna Elness

Abstract

Taking it slow: Titration of biologics in severe eosinophilic asthma a real world data report

Grgur Salai

Poster

Abstract

Switching patients with severe eosinophilic asthma from Tezepelumab to Benralizumab

Felix J.f. Herth

Poster

Abstract

Late Breaking Abstract - Clinical Remission in Patients with Severe Eosinophilic Asthma Treated with Benralizumab over 24 Months: Post Hoc Analysis of the ANANKE Study

Giorgio Walter Canonica

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}